November 2022 in “Journal of Investigative Dermatology” This pilot study suggests that lovastatin may counteract stress-induced MICA expression in hair follicles and enhance MICA shedding, potentially offering a complementary approach for alopecia areata treatment.
February 2020 in “Research Square (Research Square)” In this study, skin tags in Irish adults with morbid obesity were associated with higher blood pressure, higher HbA1c levels, and a greater prevalence of diabetes and hypertension, suggesting increased cardiovascular risk.
January 2015 in “Springer eBooks” Chronic kidney disease can cause hair loss, which may be related to zinc deficiency or certain medications, and sometimes hair grows back when the underlying issue is treated.
34 citations
,
September 2020 in “BMC Endocrine Disorders” This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.
4 citations
,
March 2020 in “BMC Research Notes” In this study of Irish adults with morbid obesity, skin tags were associated with higher blood pressure, HbA1c levels, and a greater prevalence of diabetes and hypertension, indicating increased cardiovascular risk.
60 citations
,
May 2011 in “Endocrinology and Metabolism Clinics of North America” This article discusses the association between hypertension and polycystic ovary syndrome, highlighting the need for managing related risk factors, but reports no new clinical results.
September 2023 in “International journal of women’s dermatology” This study found mixed evidence linking traction hairstyles, previous pregnancies, chemical hair relaxers, and several comorbidities to an increased risk of central centrifugal cicatricial alopecia in Black women.
November 2024 in “SKIN The Journal of Cutaneous Medicine” This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.
June 2022 in “International Journal of Health Sciences (IJHS)” This study found that a nutrition intervention was more effective than nutrition education or medication alone in reducing symptoms of PCOS, with significant improvements in body measurements and testosterone levels.
54 citations
,
August 2017 in “Gynecological Endocrinology” This review discusses treatments for polycystic ovary syndrome, including lifestyle changes, oral contraceptives, and various medications, and reports no new clinical findings; the authors highlight the potential of statins and inositol for managing symptoms.
41 citations
,
June 2010 in “Anais Brasileiros de Dermatologia” This study found that isotretinoin is a safe and well-tolerated acne treatment, with common adverse effects like cheilitis manageable through symptomatic medication and no significant changes in lipid or liver enzyme levels.
24 citations
,
January 2010 in “Endocrine Regulations” In this study, men taking 1 mg/day of finasteride for 12 months showed minor metabolic changes and slight improvements in glucose metabolism.
September 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” The document concludes that individualized treatments for hair issues are effective, certain hair changes can indicate neurocutaneous diseases, specific lotions improve skin health, laser hair removal works but needs more study on long-term effects, men's cosmetics are diverse, peeling is effective but can have side effects, and facial pigmentation is often due to overactive skin cells.
17 citations
,
January 2020 in “The World Journal of Men's Health” This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.
89 citations
,
March 2001 in “Endocrine practice” This article provides diagnosis and treatment guidelines for hyperandrogenic disorders in women but reports no new clinical results; it offers a summary of accepted scientific information and suggestions for clinical practice.
1 citations
,
February 1993 in “Nursing Standard” This article highlights that nurses may not be sufficiently aware of the potential for various drug groups, beyond cytotoxic drugs, to cause alopecia, and emphasizes the importance of early recognition of this side effect.
November 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” This study discusses the multifactorial causes of metabolic syndrome and its association with various skin conditions, indicating an increased risk of diabetes and cardiovascular issues, emphasizing the need for early lifestyle interventions and medical management.
September 2024 in “Digital Commons - University of South Florida (University of South Florida)” This study found that injecting various hormones or hormone-cholesterol mixtures into Willow Ptarmigan and White-tailed Ptarmigan led to the growth of pigmented feathers instead of the usual white winter feathers, suggesting hormonal influence on plumage color changes.
October 1997 in “Baylor University Medical Center Proceedings” Obesity in the U.S. is largely influenced by diet and exercise, certain medications can improve heart procedures and hair growth, and major teaching hospitals have better patient outcomes.
November 2024 in “Apple Academic Press eBooks” In this chapter, the authors emphasize the significant therapeutic roles attributed to Allium tuberosum due to its rich phytochemicals, detailing potential benefits against various conditions like diabetes, cancer, and liver dysfunction, as well as its applications in anticoagulation, muscle cell proliferation, and sensory perception mediation.
October 2015 in “Elsevier eBooks” Spironolactone can cause side effects like high potassium levels and breast enlargement, and patients need careful monitoring.
22 citations
,
August 2002 in “The American Journal of Medicine” Atorvastatin may cause hair loss in some people.
In this study, researchers found that biotin levels increase with age but not gender, and there is a notable negative relationship between biotin levels and triglyceride levels, suggesting biotin should be checked in patients with high triglyceride levels.
9 citations
,
January 2021 in “Advances in Experimental Medicine and Biology” This article discusses the potential health benefits of astaxanthin, such as its antioxidant properties and diverse applications in chronic conditions, but it reports no new clinical results.
May 2015 in “Journal of the American Academy of Dermatology” Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.
391 citations
,
September 2015 in “Journal of Clinical Lipidology” This document extends previous recommendations by the National Lipid Association for managing dyslipidemia, focusing on lifestyle therapies, special patient groups, and strategies to enhance adherence and patient outcomes.
64 citations
,
January 2001 in “Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy” This review discusses the diverse pharmacological activities of misoprostol across multiple health conditions but reports no new clinical data, highlighting potential applications beyond its traditional uses.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
25 citations
,
July 2019 in “Experimental Dermatology” This review discusses the role of cholesterol homeostasis in hair follicle biology and its potential connections to various hair disorders, but it reports no new findings.
14 citations
,
September 2019 in “Eye” This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.